Novartis Aktie
128,14
EUR
-0,16
EUR
-0,12
%
128,16
EUR
-0,82
EUR
-0,64
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novartis Aktie Analyse
| 20.01.20 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 16.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 16.01.20 | Novartis Underweight | Barclays Capital | |
| 16.01.20 | Novartis Neutral | Credit Suisse Group | |
| 09.01.20 | Novartis Hold | Deutsche Bank AG | |
| 06.01.20 | Novartis verkaufen | Morgan Stanley | |
| 06.01.20 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.12.19 | Novartis buy | Jefferies & Company Inc. | |
|
Werbung
|
|||
| 16.12.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.12.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 12.12.19 | Novartis Hold | Deutsche Bank AG | |
| 09.12.19 | Novartis Hold | Deutsche Bank AG | |
| 06.12.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.12.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 27.11.19 | Novartis Hold | HSBC | |
| 26.11.19 | Novartis Hold | HSBC | |
| 26.11.19 | Novartis Hold | Deutsche Bank AG | |
| 25.11.19 | Novartis Neutral | Credit Suisse Group | |
| 25.11.19 | Novartis Neutral | UBS AG | |
| 25.11.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 25.11.19 | Novartis buy | Jefferies & Company Inc. | |
| 18.11.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.10.19 | Novartis Hold | Deutsche Bank AG | |
| 30.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 25.10.19 | Novartis Underweight | Barclays Capital | |
| 24.10.19 | Novartis Neutral | UBS AG | |
| 24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.10.19 | Novartis Neutral | Credit Suisse Group | |
| 23.10.19 | Novartis Underweight | Barclays Capital | |
| 23.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 22.10.19 | Novartis buy | Jefferies & Company Inc. | |
| 22.10.19 | Novartis Underweight | Morgan Stanley | |
| 22.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Novartis Neutral | UBS AG | |
| 22.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.10.19 | Novartis Hold | Deutsche Bank AG | |
| 21.10.19 | Novartis Underweight | Morgan Stanley | |
| 18.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 18.10.19 | Novartis Neutral | UBS AG | |
| 17.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.10.19 | Novartis Neutral | UBS AG | |
| 07.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 16.09.19 | Novartis Hold | Deutsche Bank AG | |
| 13.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 13.09.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
Werbung
Werbung